ConcertAI, a Boston MA-based leader in AI and Real-World Data (RWD) solutions for life sciences and healthcare, announced the closing of a $150 million Series C investment from Sixth Street, a leading global investment firm, at a $1.9 billion valuation.
This Series C investment focuses on the intersection of healthcare and technology and is further validation of the strength of its customer base, strategy, and performance.
Adam Kaye, Managing Director of Sixth Street, will join ConcertAI's Board of Directors, while Lee Mooney, Managing Director of Sixth Street, will serve on the Board as an observer.
Company: ConcertAI LLC
Round: Series C
Funding Month: March 2022
Lead Investors: Sixth Street
Company Website: https://www.concertai.com/
Software Category: AI and real-world data (RWD) solutions
About the Company: ConcertAI is the world's leading provider of AI solutions for life sciences and healthcare organizations and RWD SaaS solutions. ConcertAI's mission is to broadly advance the goals of precision medicine, accelerate the delivery of innovative new therapies, generate evidence to support regulatory and reimbursement decisions, support provider clinical decisions, and improve clinical outcomes for patients. Over the past 36 months, the company has expanded its customer base and partnerships with full lifecycle SaaS solutions to more than 45 life sciences companies and contract research organizations (CROs): It has supported approximately 40 new product launches, reduced time to therapy by 10%, and reduced time to study design and anticipated clinical trial completion by up to 25%. ConcertAI has become one of the fastest-growing companies providing high-quality software-as-a-service (SaaS) and data solutions to life science and biopharma companies, leading healthcare providers, contract research organizations, medical societies, and regulatory agencies in the US, Europe, and Japan.